Clinical Trial Update: Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder [Phase 2, Phase 3]

View source ↗

Summary

An extension study of pimavanserin for irritability associated with autism spectrum disorder was terminated, and the results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autism Spectrum Disorder

Drugs mentioned

• Pimavanserin (pimavanserin)

Snippet

Sponsor: ACADIA Pharmaceuticals Inc. | Conditions: Irritability Associated With Autism Spectrum Disorder | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2025-12-03